<DOC>
	<DOCNO>NCT00964132</DOCNO>
	<brief_summary>The purpose study determine whether NRX 194204 effective treatment advance Non-Small Cell Lung Cancer ( NSCLC ) .</brief_summary>
	<brief_title>Oral NRX 194204 Study Patients With Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Numerous study pre-clinical model human clinical trial clearly establish potential use rexinoids treatment prevention cancer . NRX 194204 , second generation rexinoid , highly potent specific activator RXRs . Because NRX 194204 significantly selective RXRs relative RARs first generation approve drug , associate few adverse event clinical use . This study seek investigate NRX 194204 monotherapy patient fail 2 prior therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Male female , age ≥ 18 year Histologically confirm advanced stage III IV NSCLC recurrent progress treatment . Failure least 2 NSCLC treatment regimens Unidimensionally measurable NSCLC define least one lesion measure least one dimension ( long diameter record ) ≥ 2cm conventional technique ≥ 1cm spiral CT scan . Patients eligible disease free previous malignancy , previous NSCLC , great two year . Patients history prior basal cell carcinoma skin preinvasive carcinoma cervix exclude . Karnofsky performance status ≥ 60 ( Attachment 14.4 ) ECOG performance status 02 Life expectancy &gt; 12 week . Able swallow capsule form drug . Hematology : Hemoglobin &gt; 8.5 g/dl ; Platelets &gt; 100,000 cells/mm3 ; Neutrophils &gt; 1500 cells/mm3 ; PT PTT within normal limit , except patient receive Coumadin thromboembolic prophylaxis , INR le 2 allowable . Biochemistry : Total bilirubin &lt; 1.5 x ULN ; AST/ALT &lt; 3.0 x ULN ; Serum creatinine &lt; 2.0 mg/dl ; Serum calcium &lt; 11.5 mg/dl ; Fasting serum triglyceride &lt; 2.5 x ULN . Negative urine pregnancy test woman childbearing potential screening Day 1 , agreement woman men reproductive potential use two reliable form contraception therapy 1 month follow discontinuation therapy unless abstinence choose birth control method . Able follow study instruction , accessible treatment followup , likely complete study requirement . Significant medical history unstable medical condition ( congestive heart failure , recent myocardial infarction within 3 month , unstable angina , active systemic infection , uncontrolled hypertension ) . Patients control diabetes allow . Prior treatment bexarotene ( Targretin ) NRX 194204 . Current enrollment investigational drug device study participation study within 21 day entry study . Known sensitivity ingredient study medication . Known HIVpositive patient . Females pregnant , nursing , plan pregnancy . Major surgery within previous 4 week ; large field radiation therapy ( &gt; 25 % patient 's total marrow ) chemotherapy ( include investigational agent participation another clinical study ) within previous 3 week ; mitomycin C nitrosoureas within 6 week . In instance , patient must fully recover acute toxicity relate prior therapy . Systemic retinoid therapy , Vitamin A dosages &gt; 15,000 IU per day , previous 4 week . Patients history pancreatitis significant risk develop pancreatitis ( e.g. , uncontrolled hyperlipidemia , excessive alcohol consumption , uncontrolled diabetes mellitus , medication know increase triglyceride level associate pancreatic toxicity ) . Primary brain tumor , active brain metastasis include progression last scan evidence cerebral edema , clinical symptom brain metastasis . Condition situation , investigator 's opinion , may put patient significant risk , may confound study result , may interfere significantly patient 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Rexinoid</keyword>
	<keyword>NRX194204</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>RXR</keyword>
</DOC>